Studies | Case | Age | Gender | Co | F | CP | Outcome | AE | CI | Type of TI | TI |
---|---|---|---|---|---|---|---|---|---|---|---|
Year* | (T/C) | (M/F) | (d) | ||||||||
Sun 2007 [24] | 64(34/30) | 37~62 | T:13/21C:11/19 | 56 | 0 | y | AF,TT | U | RT | Chinese patent drug | Shenwuguanxinning granules 15Â g tid + RT |
Ge 2011 [25] | 39(19/20) | 45~56 | 10/29 | 28 | 0 | y | A,AF,TTET-1 | U | RT | Decoction | Nourishing Qi and Blood Decoction 1 150Â mL qd + RT |
Peng 2011 [26] | 46(23/23) | 35~65 | 18/28 | 56 | 0 | y | A,AF,TT | N | RT | Chinese patent drug | Xinnaotong capsule 0.8Â g bid + RT |
Niu 2008 [27] | 50(30/20) | 35~65 | 21/29 | 28 | 0 | y | A,AF,ECG,TT,TCM | N | RT | Chinese patent drug | Xinxuean granules 15Â g tid + RT |
Gao 2005 [28] | 63(33/30) | 45~64 | 0/63 | 28 | 0 | y | A | U | RT | Decoction | Xiaoyao decoction2 150Â mL bid |
Xu 2011 [29] | 30(15/15) | 35~60 | 10/20 | 28 | 0 | y | A,AF,TT | U | RT | Chinese patent drug | Wenxin granules3 9Â g, tid + RT |
Bi 2003 [30] | 60(30/30) | 44~61 | 27/33 | 28 | 6Â m | y | A | N | RT | Chinese patent drug | Tongxinluo 1.52Â g, tid |
Wang 2009 [31] | 55(28/27) | 43~65 | T: 5/23 C: 3/24 | 14 | 0 | y | A,ECG,TCM,TTET-1,NOhs-CRP | N | RT | Decoction | Kuanxionghuoxue decoction4 150Â ml bid + RT |
Xu LJ 2002 [32] | 56(36/20) | 31~48 | T:23/13 C:13/7 | 7 | 7d | y | A,ET-1,Holter | U | RT | Chinese patent drug | Quanshi capsule 1.5Â g tid |
Liu 2008 [33] | 58(38/20) | 36~55 | 37/21 | U | 0 | y | A,ECG | U | RT | Chinese patent drug | Naoxintong tablets, 1.6Â g, tid |
Zhang 2002 [34] | 40(20/20) | 30~59 | 18/22 | 15 | 0 | y | A,ECG | U | RT | Decoction | Taohongsiwu decoction5 150Â mL qd |
Lu 2007 [35] | 114(72/72 | 18~60 | 56/88 | 84 | 0 | y | TT,ECG | N | RT | Chinese patent drug | Tongxinluo capsule 1.52Â g tid |
Zhu 2003 [36] | 60(30/30) | 30~59 | 38/22 | 15 | 0 | y | A,ECG | U | RT | Decoction | Xuefuzhuyu decoction 6150Â mL qd |
Liang 2005 [37] | 42(21/21) | 51~60 | 12/30 | 28 | 0 | y | A,AF, TCM,TT hs-CRP | N | RT placebo | Chinese patent drug | Danshen tablets, three tablets per time, tid + RT |
Yuan 2008 [38] | 40(20/20) | 48~67 | T:9/11 C:13/7 | 28 | 0 | y | AF,TT | U | RT | Injection | Danhong injection 30Â ml + 5% glu or 0.9% NaCI 250Â ml, iv, qd |
Wang GF 2008 [39] | 36(18/18) | 33~70 | T:3/15 C:2/16 | 28 | 0 | y | AF,TT,CRP,ET-1,NO | N | RT | Decoction | Guanmailing decoction7 150Â ml bid+ RT |
Zhang SL 2008 [40] | 72(36/36) | 37~62 | T:6/30 C:3/31 | 20 | 0 | y | A | N | R | Chinese patent drug | Guanmaining 8 10Â ml tid + xiaoyao pill, 8 pills, tid+ RT |
Zhang XY 2008 [41] | 68(48/28) | 42~58 | T:11/37 C:6/14 | 21 | 0 | y | A,ECG | U | RT | Decoction | Individualized Chinese formulas against different patterns of syndrome9 150 ML bid+ RT |
Wu 2010 [42] | 50(26/24) | 39~50 | T:10/16 C: 9/15 | 15 | 0 | y | AF,TT, CRP | N | RT | Injection | Shuxuening injection 20Â ml+ 0.9% NaCI 250Â ml, iv, qd+ RT |
Li 2009 [43] | 68(36/32) | 49~64 | T:16/20 C:14/18 | 30 | 0 | y | ECG, blood lipid, ET-1,No, | Y | RT | Chinese patent drug | Tongxinluo capsule, 2.14Â g, tid + RT |
Feng 2005 [44] | 32(16/16) | 37~51 | T:7/9 C:8/8 | 28 | 0 | y | AF,TT ET-1 | U | RT | Chinese patent drug | Tongxinluo capsule, 1.14Â g tid+ RT |